Tirzepatide Subcutaneous Injection 15mg (Mounjaro® / マンジャロ皮下注15mgアテオス)

JPY ¥26,950

Japanese long-acting GIP/GLP-1 receptor agonist (Tirzepatide 15mg). Subcutaneous injection for type 2 diabetes mellitus. 0.5mL x 2 kits. Mfd. by Eli Lilly Japan K.K., Japan.

20 in stock

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥24,794
10 - 19 12% JPY ¥23,716
20 + 18% JPY ¥22,099
SKU: TIR-15-INJ Category:

Description

Product Overview / 商品概要

Mounjaro Subcutaneous Injection 15mg ATEOS (マンジャロ皮下注15mgアテオス)
Generic: Tirzepatide / チルゼパチド
Therapeutic Category: Long-acting GIP/GLP-1 receptor agonist / 持続性GIP/GLP-1受容体作動薬
Manufactured by: Eli Lilly Japan K.K. / 日本イーライリリー株式会社

Composition & Specification / 組成・規格

Active Ingredient: Tirzepatide 15mg per kit / 1キット中 チルゼパチド15mg
Additives: Disodium hydrogen phosphate heptahydrate 0.7mg, Sodium chloride 4.1mg, Hydrochloric acid (suitable quantity), Sodium hydroxide (suitable quantity) / リン酸水素二ナトリウム七水和物0.7mg、塩化ナトリウム4.1mg、塩酸適量、水酸化ナトリウム適量
Appearance: Colorless to slightly yellow to slightly brown, clear or slightly opalescent liquid, pH 6.5-7.5, osmotic pressure ratio approximately 1 (relative to physiological saline)
外観: 無色~微黄色~微褐色の澄明又はわずかに乳白光を呈する液、pH6.5~7.5、浸透圧比約1(生理食塩液に対する比)

Indications / 効能効果

EN: Type 2 diabetes mellitus
JA: 2型糖尿病

Dosage and Administration / 用法用量

EN: Usually, for adults, administer 5mg of tirzepatide once weekly as a maintenance dose by subcutaneous injection. Start with 2.5mg once weekly, and after 4 weeks, increase to 5mg once weekly. Dose may be adjusted as appropriate according to the patient’s condition. If the effect is insufficient at 5mg once weekly, the dose may be increased by 2.5mg at intervals of 4 weeks or more. The maximum dose is 15mg once weekly.
JA: 通常、成人には、チルゼパチドとして週1回5mgを維持用量とし、皮下注射する。ただし、週1回2.5mgから開始し、4週間投与した後、週1回5mgに増量する。なお、患者の状態に応じて適宜増減するが、週1回5mgで効果不十分な場合は、4週間以上の間隔で2.5mgずつ増量できる。ただし、最大用量は週1回15mgまでとする。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product; patients with diabetic ketoacidosis, diabetic coma or pre-coma, or type 1 diabetes mellitus; emergency situations such as severe infection or surgery
JA: 本剤の成分に対し過敏症の既往歴のある患者、糖尿病性ケトアシドーシス・糖尿病性昏睡又は前昏睡・1型糖尿病の患者、重症感染症・手術等の緊急の場合

Regulatory Information / 規制情報

Approval No.: 30400AMX00425
Sales Started: June 2023 / 2023年6月
Classification Code: 872499
Storage: Store at 2-8°C / 2~8℃で保存
Shelf Life: 24 months / 24ヵ月

Packaging / 包装

Main Package (for sale): 0.5mL x 2 kits / 0.5mL×2キット
Other Available Packages (by special order): 0.5mL x 2 kits

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg
generic_name_ja

チルゼパチド

generic_name_en

Tirzepatide

dosage_form_ja

注射剤

dosage_form_en

Injection

strength

15mg

approval_number

30400AMX00425

manufacturer

Eli Lilly Japan K.K.

classification_code

872499

storage

Store at 2-8°C

shelf_life

24 months

main_packaging

0.5mL x 2 kits

all_packaging

0.5mL x 2 kits

Reviews

There are no reviews yet.

Be the first to review “Tirzepatide Subcutaneous Injection 15mg (Mounjaro® / マンジャロ皮下注15mgアテオス)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Tirzepatide Subcutaneous Injection 15mg (Mounjaro®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.